PRE VS IOBT Stock Comparison

Performance

PRE
10/100

PRE returned -86.81% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

IOBT
10/100

IOBT returned -68.33% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.

Technicals

PRE
36/100

PRE receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

IOBT
36/100

IOBT receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

PRE
44/100

PRE has missed earnings 2 times in the last 20 quarters.

IOBT
26/100

IOBT has missed earnings 3 times in the last 20 quarters.

Profit

PRE
13/100

Out of the last 10 quarters, PRE has had 2 profitable quarters and has increased their profits year over year on 1 of them.

IOBT
10/100

Out of the last 12 quarters, IOBT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

PRE
55/100

PRE has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

IOBT
40/100

IOBT has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Prenetics Global Limited Class A Ordinary Share Summary

Nasdaq / PRE

Healthcare

Medical - Diagnostics & Research

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

IO Biotech, Inc. Common Stock Summary

Nasdaq / IOBT

Healthcare

Biotechnology

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Power up your portfolio